-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga·08/19/2026 09:56:49
Listen to the news
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.